MedPacto has obtained a domestic patent for the manufacture of Vactosertib
Mar 09, 2023
Can simplify synthesis steps and facilitate a manufacturing process… cost per unit in the commercialization stage for mass production can be lowered
MedPacto(CEO Seong-jin Kim), a genome-based drug discovery and a clinical-stage biotechnology company, announced that they have obtained a domestic patent for the manufacture of Vactosertib on March 9th.
The patent is for “Intermediates useful for the synthesis of TGF-β inhibitors and a method of preparing TGF-β inhibitors using the same”.
This patent is for a manufacturing method suitable for the mass production of Vactosertib, which is more cost-effective in a way that it simplifies the synthesis steps and purification methods resulting in improving production yield compared to the existing methods.
The patent is expected to be used in the upcoming commercialization stage.
“Our newly developed manufacturing method is expected to simplify the reaction stages and improve production yield resulting in lower cost per unit in the commercialization stage” stated a MedPacto representative.
MedPacto is preparing for a global phase 3 clinical trial for colorectal cancer in combination therapy with Vactosertib and Keytruda. The phase 1/2 clinical trial for Vactosertib as a single agent in patients with recurrent, refractory, or progressive osteosarcoma has been approved by the FDA and the Ministry of Food and Drug Safety of the Republic of Korea.